Mayne enters US women’s health market with NASDAQ-listed partner for $205m; shareholders spookedIn a deal the company expects to be immediately material to its own revenues and profits, Australia’s Mayne Pharma (ASX:MYX) is entering the US women’s healthcare product market with NASDAQ-listed partner TherapeuticsMD. Executing a licencing agreement with Therapeutics, Mayne will hand the former $205.5m to fund the product-line acquisition.Payments to Therapeutics MD by Mayne will be made on sales-based milestones; for every US$100m in revenue made each year, Mayne will need to hand TherapeuticsMD $5m. Mayne will also pay royalties of US$3m a year for 12 years.
Mayne Pharma has an extensive women’s health portfolio focused on contraceptives.
Add MYX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$7.27 |
Change
0.000(0.00%) |
Mkt cap ! $618.4M | |||
| Open | High | Low | Value | Volume |
| $7.27 | $7.43 | $7.23 | $640.8K | 87.69K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 457 | $7.25 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $7.28 | 475 | 1 |
View Market Depth
| Last trade - 16.10pm 07/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$7.24 |
Change
0.000 ( 0.41 %) |
||||
| Open | High | Low | Volume | ||
| $7.34 | $7.43 | $7.23 | 18585 | ||
| Last updated 15.59pm 07/05/2024 ? | |||||
| MYX (ASX) Chart |